文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

肥厚型心肌病伴左心室心尖部室壁瘤的CMR特征与预后比较

[Comparison on CMR characteristics and clinical prognosis between hypertrophic cardiomyopathy patients with and without left ventricular apical aneurysms].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2019-01-01

该回顾性研究比较了18例HCM伴左心室心尖部室壁瘤患者与18例年龄性别匹配的单纯HCM患者的CMR特征及长期预后。结果显示伴室壁瘤组延迟强化量更大、左心室射血分数和心尖室壁厚度更低,随访期间主要不良心血管事件更多,提示该亚组预后更差。

要点

  • HCM伴左心室心尖部室壁瘤患者延迟强化量显著高于单纯HCM患者。
  • 伴室壁瘤组左心室射血分数和心尖室壁厚度均显著低于单纯HCM组。
  • 伴室壁瘤组随访期间主要不良心血管事件发生率更高,预后更差。

核心结论

  • HCM伴左心室心尖部室壁瘤患者延迟强化量明显增多且临床预后较差。

研究设计与样本

  • 按照年龄、性别匹配18例单纯HCM患者作为单纯HCM组,收集临床资料及CMR成像结果并进行门诊或电话随访。

主要发现

  • 伴室壁瘤组有明显家族史的比例较单纯HCM组高[55.6%(10/18)比22.2%(4/18),P=0.04]。
  • 伴室壁瘤组心电图ST-T改变和异常Q波的比例均较单纯HCM组高(P均<0.01)。
  • 伴室壁瘤组CMR测得的左心室舒张末期横径及舒张末期容积指数均较单纯HCM组高(P均<0.05)。
  • 伴室壁瘤组延迟强化量显著大于单纯HCM组[(25.26±10.60)%比(15.78±7.33)%,t=3.12,P=0.004]。
  • 伴室壁瘤组左心室射血分数和心尖室壁厚度均较单纯HCM组小[分别为(54.4±10.6)%比(67.5±7.6)%,t=-4.28,P<0.000 1及(3.11±1.05)mm比(5.46±1.94)mm,t=-4.49,P<0.000 1]。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To compare the imaging characteristics and long-term prognosis in hypertrophic cardiomyopathy(HCM) patients with or without left ventricular apical aneurysm(LVAA). Methods: Retrospectively analyzed the clinical data from 18 patients diagnosed as HCM complicating with LVAA(HCM-LVAA group), hospitalized and underwent cardiac magentic resonance (CMR) examination in Fuwai Hospital between December 2012 and December 2016. Eighteen age and gender matched patients with HCM diagnosed by CMR served as control(HCM group). Outpatient and in-hospital clinical data as well as follow up results were compared. The major adverse cardiovascular events were defined as malignant arrhythmia events (including sudden cardiac death, ventricular flutter/ventricular fibrillation) and heart failure events (including heart transplantation, progressive heart failure). Results: Compared with HCM group, patients in HCM-LVAA group had a more positive family history of HCM(P=0.04), higher incidence of ST-T segment changes and abnormal Q wave in electrocardiograms (both P<0.01), the CMR derived left ventricular end-diastolic transverse diameter and end-diastolic volume index were also significantly higher (both P<0.05), and delayed enhancement was more significant ((25.26±10.60)% vs. (15.78±7.33)%, t=3.12, P=0.004) in HCM-LVAA group. Moreover, the left ventricular ejection fraction ((54.4±10.6)% vs. (67.5±7.6)%, t=-4.28, P<0.000 1) and the thickness of the apical wall ((3.11±1.05) mm vs. (5.46±1.94) mm, t=-4.49, P<0.000 1) were significantly lower in HCM-LVAA group than in HCM group. The mean follow-up duration was (3.46±1.64) years, 4 patients in HCM-LVAA group (22.2%) developed 4 cardiovascular events, including 1 sudden cardiac death, 3 progressive heart failures. One patient in HCM group developed progressive heart failure. Conclusion: The prognosis of the HCM complicating with LVAA patients is worse than that of HCM patients without LVAA, and the amount of late gadolinium enhancement is higher than that of HCM patients without LVAA. 目的: 探讨肥厚型心肌病(HCM)伴左心室心尖部室壁瘤患者的心脏磁共振(CMR)成像特征及临床预后。 方法: 回顾性分析2012年12月至2016年12月于阜外医院接受CMR扫描的HCM患者共2 028例,其中18例患者诊断为HCM伴左心室心尖部室壁瘤作为HCM伴左心室心尖部室壁瘤组,按照年龄、性别匹配18例单纯HCM患者作为单纯HCM组。分别收集两组患者的临床资料及CMR成像结果,并对入选患者进行门诊或电话随访,记录其主要不良心血管事件的发生情况。主要不良心血管事件定义为恶性心律失常事件[包括心脏性猝死、心室扑动/颤动)及心力衰竭事件(包括心脏移植、进展性心力衰竭)。 结果: HCM伴左心室心尖部室壁瘤组患者有明显家族史的比例较单纯HCM组高[55.6%(10/18)比22.2%(4/18),P=0.04],心电图示ST-T改变和异常Q波的比例亦均较单纯HCM组高(P均<0.01)。HCM伴左心室心尖部室壁瘤组患者CMR测得的左心室舒张末期横径及舒张末期容积指数均较单纯HCM组高(P均<0.05),延迟强化的量亦显著大于单纯HCM组[(25.26±10.60)%比(15.78±7.33)%,t=3.12,P=0.004],而其左心室射血分数和心尖室壁厚度则均较单纯HCM组小[分别为(54.4±10.6)%比(67.5±7.6)%,t=-4.28,P<0.000 1及(3.11±1.05)mm比(5.46±1.94)mm,t=-4.49,P<0.000 1]。随访时间为(3.46±1.64)年,HCM伴左心室心尖部室壁瘤组18例患者中出现4次主要不良心血管事件,包括1次心脏性猝死和3次进展性心力衰竭,而单纯HCM组18例患者中仅出现1次进展性心力衰竭。 结论: HCM伴左心室心尖部室壁瘤患者延迟强化量明显增多且临床预后较差。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Song YY, Lu MJ, Li L, et al. [Comparison on CMR characteristics and clinical prognosis between hypertrophic cardiomyopathy patients with and without left ventricular apical aneurysms]. Zhonghua Xin Xue Guan Bing Za Zhi. 2019. PMID: 30897879. doi:10.3760/cma.j.issn.0253-3758.2019.03.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。